Although AAV9 is not a kidney-specific vector and the delivery tool for kidney targets are not as efficient as that for heart and liver targets [41], the effective amelioration of DKD observed in AAV9-Bdh1-GFP-injected db/db mice strongly suggests that AAV9-mediated gene-targeting therapy is a promising treatment. The gene discussed is BDH1; the disease is diabetic kidney disease.